iBio: Pay

iBio paid its 3 named executives $3.0M in total in FY2025 (Jun). CEO Dr. Martin B. Brenner was paid $1.5M of that.

Pay$100 in the stock at the end of FY21 → $1
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Dr. Martin B. BrennerChief Executive Officer and Chief Scientific Officer
FY2025 (Jun)
FY2024 (Jun)
FY2022 (Jun)
3 years
Felipe DuranChief Financial Officer
FY2025 (Jun)
FY2024 (Jun)
FY2023 (Jun)
3 years
Marc BanjakChief Legal Officer
FY2025 (Jun)
1 year

CEO pay against the pay peers

In FY2024 (Jun), the median CEO pay of the 4 peers with pay on file was $2.7M. The CEO of iBio was paid $1.3M, 54% below the median.

  1. 1Savara
  2. 2Agenus
  3. 3CytomX Therapeutics
  4. 4Medicinova
  5. 5iBio
  6. 6Alanos TherapeuticsNot disclosed
  7. 7Arcturus Therapeutics HoldingsNot disclosed
  8. 8CEL-SCINot disclosed
  9. 9CorbusNot disclosed
  10. 10DyadicNot disclosed
  11. 11DynavaxNot disclosed
  12. 12KaryopharmNot disclosed
  13. 13MorphicNot disclosed
  14. 14NightHawk BiosciencesNot disclosed
  15. 15Sorrento TherapeuticsNot disclosed
  16. 16Sutro BiopharmaNot disclosed
  17. 17Y -mAbs TherapeuticsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.